These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 16689107)

  • 1. [Quo vadetis coxibs?].
    Grazio S; Anić B
    Reumatizam; 2005; 52(1):17-27. PubMed ID: 16689107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Athletes, NSAID, coxibs, and the gastrointestinal tract.
    Lilly KF
    Curr Sports Med Rep; 2010; 9(2):103-5. PubMed ID: 20220352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk.
    Vardeny O; Solomon SD
    Cardiol Clin; 2008 Nov; 26(4):589-601. PubMed ID: 18929233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond.
    Coruzzi G; Venturi N; Spaggiari S
    Acta Biomed; 2007 Aug; 78(2):96-110. PubMed ID: 17933277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
    Hur C; Chan AT; Tramontano AC; Gazelle GS
    Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.
    Hermann M; Ruschitzka F
    Ann Med; 2007; 39(1):18-27. PubMed ID: 17364448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase-2 inhibitors and cardiovascular risk.
    Solomon SD
    Curr Opin Cardiol; 2006 Nov; 21(6):613-7. PubMed ID: 17053413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NSAID-induced gastrointestinal damage and the design of GI-sparing NSAIDs.
    Wallace JL; Vong L
    Curr Opin Investig Drugs; 2008 Nov; 9(11):1151-6. PubMed ID: 18951293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
    Moore RA; Derry S; Phillips CJ; McQuay HJ
    BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The murky waters of the coxibs: a review of the current state of play.
    Ostor AJ; Hazleman BL
    Inflammopharmacology; 2005; 13(4):371-80. PubMed ID: 16354390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [What is new about nonsteroidal antiinflamatory drugs?].
    Dzielska-Olczak M
    Pol Merkur Lekarski; 2007 Dec; 23(138):454-8. PubMed ID: 18432131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.
    Joshi GP; Gertler R; Fricker R
    Anesth Analg; 2007 Dec; 105(6):1793-804, table of contents. PubMed ID: 18042885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs.
    Jones R; Rubin G; Berenbaum F; Scheiman J
    Am J Med; 2008 Jun; 121(6):464-74. PubMed ID: 18501223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The safety of COX-2 inhibitors].
    Lakatos G; Herszényi L; Tulassay Z
    Orv Hetil; 2008 Aug; 149(33):1539-47. PubMed ID: 18687572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Appropriate use of NSAIDs: considering cardiovascular risk in the elderly.
    Stillman MJ; Stillman MT
    Geriatrics; 2007 Mar; 62(3):16-21. PubMed ID: 17346094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular risks of cyclooxygenase inhibition.
    Stacy ZA; Dobesh PP; Trujillo TC
    Pharmacotherapy; 2006 Jul; 26(7):919-38. PubMed ID: 16803424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of COX-2 anti-inflammatory drugs on soft tissue healing: a review of the literature.
    Randelli P; Randelli F; Cabitza P; Vaienti L
    J Biol Regul Homeost Agents; 2010; 24(2):107-14. PubMed ID: 20487623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].
    van den Bemt BJ; Benraad HB; Rasker JJ
    Ned Tijdschr Geneeskd; 2007 May; 151(19):1062-7. PubMed ID: 17552414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cyclooxygenase inhibition on the gastrointestinal tract.
    Radi ZA; Khan NK
    Exp Toxicol Pathol; 2006 Nov; 58(2-3):163-73. PubMed ID: 16859903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-proliferative potency of celecoxib is not a class effect of coxibs.
    Schiffmann S; Maier TJ; Wobst I; Janssen A; Corban-Wilhelm H; Angioni C; Geisslinger G; Grösch S
    Biochem Pharmacol; 2008 Jul; 76(2):179-87. PubMed ID: 18547544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.